Backed by our 3 Health Canada licenses, we ensure the highest of standard by integrating and controlling all aspects of the supply chain from sourcing natural inputs to research in our licensed R&D laboratory
Psilobrain Therapeutics Inc. is a Canadian biotech company that uses the latest in psychedelic medicine to design products that facilitate evidence-based healing & wellness
Psilobrain Therapeutics Inc. is unlocking the global potential of psychedelics through highest quality APIs (Active Pharmaceutical Ingredient)
Backed by a leading team with proven execution creating APIs and delivering investor value. Senior management had led billions of combined B2B pharmaceutical sales
Supply agreements with leading pharmaceutical organizations around the globe. Established relationships and experience as a leading API supplier
Psilobrain is committed to our Drug Development Program, with 3 provisional patents and numerous preclinical studies in various stages of research and data collection. Psilobrain is an active participant in the pharmaceutical, nutraceutical, and psychedelic wellness industries.
By working closely with our partners, we deliver comprehensive solutions that meet the unique needs of the market.
Our Management and Advisory team are industry veterans in the pharmaceutical and consumer goods industries. Members of our team have held C-suite and other senior positions within companies around the globe.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Lorem ipsum dolor sit amet consecte adipiscing elit amet hendrerit pretium nulla sed enim iaculis mi.
Of Combined experience in industry specific sectors
Pharma Business Development Exp.
Retail and Distribution Experience
Health and Wellness Experience
Marketing Industry Experience
Psilobrain’s wholly-owned subsidiary, Nectar Health Sciences – Laboratories Division Inc., is one of the first to have a Licensed Dealer Health Canada designation and a state of the art lab in Victoria, BC. This unique suite of licenses allows for the research and development, possession and distribution of psilocybin, psilocin, Ketamine, DMT, and MDMA.
Psilobrain Therapeutics has 3 Matter of Composition Patents, inclusive of 2 PCTs. Proof-of-Concept research for 2 of its drugs.
A fully licensed laboratory in Victoria, BC with 3 Health Canada Licenses for Research and Development and Controlled Substances Distribution
Psilobrain Therapeutics has Clinical Partnerships that represent over 500 patients seeking psychedelic therapy evidence based counselling
Estimated 10M people suffer TBI (Traumatic Brains Injury) Globally
Oncology Indication is an >$45B market size opportunity
Est. to impact 22% of the population.
Receiving orphan drug status allows Psilobrain to significantly reduce number of patients required, cost and time to reach FDA approval.
Our team has put together a comprehensive overview of our operations, highlighting our competitive advantages and market opportunities.
